CD4 and breast carcinoma: To further gain insight into the mechanistic basis of combination therapy in the 4T1 breast cancer model, we harvested draining lymph nodes and stained with fluorescent dye-conjugated anti-CD3, anti-CD4, anti-CD8, anti-CD44, and anti-CD62L antibodies for flow cytometry.